Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration.

Meliani A, Boisgerault F, Hardet R, Marmier S, Collaud F, Ronzitti G, Leborgne C, Costa Verdera H, Simon Sola M, Charles S, Vignaud A, van Wittenberghe L, Manni G, Christophe O, Fallarino F, Roy C, Michaud A, Ilyinskii P, Kishimoto TK, Mingozzi F.

Nat Commun. 2018 Oct 5;9(1):4098. doi: 10.1038/s41467-018-06621-3.

2.

Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy.

Ilyinskii PO, Kovalev GI, O'Neil CP, Roy CJ, Michaud AM, Drefs NM, Pechenkin MA, Fu FN, Johnston LPM, Ovchinnikov DA, Kishimoto TK.

PLoS One. 2018 Jun 1;13(6):e0197694. doi: 10.1371/journal.pone.0197694. eCollection 2018.

3.

Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis.

LaMothe RA, Kolte PN, Vo T, Ferrari JD, Gelsinger TC, Wong J, Chan VT, Ahmed S, Srinivasan A, Deitemeyer P, Maldonado RA, Kishimoto TK.

Front Immunol. 2018 Mar 2;9:281. doi: 10.3389/fimmu.2018.00281. eCollection 2018.

4.

Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance.

Kishimoto TK, Maldonado RA.

Front Immunol. 2018 Feb 20;9:230. doi: 10.3389/fimmu.2018.00230. eCollection 2018. Review.

5.

Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity.

Mazor R, King EM, Onda M, Cuburu N, Addissie S, Crown D, Liu XF, Kishimoto TK, Pastan I.

Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E733-E742. doi: 10.1073/pnas.1717063115. Epub 2018 Jan 8. Review.

6.

A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease.

Lim HH, Yi H, Kishimoto TK, Gao F, Sun B, Kishnani PS.

Mol Genet Metab Rep. 2017 Jul 23;13:18-22. doi: 10.1016/j.ymgmr.2017.03.005. eCollection 2017 Dec.

7.

Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.

Kishimoto TK, Ferrari JD, LaMothe RA, Kolte PN, Griset AP, O'Neil C, Chan V, Browning E, Chalishazar A, Kuhlman W, Fu FN, Viseux N, Altreuter DH, Johnston L, Maldonado RA.

Nat Nanotechnol. 2016 Oct;11(10):890-899. doi: 10.1038/nnano.2016.135. Epub 2016 Aug 1.

PMID:
27479756
8.

Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance.

Maldonado RA, LaMothe RA, Ferrari JD, Zhang AH, Rossi RJ, Kolte PN, Griset AP, O'Neil C, Altreuter DH, Browning E, Johnston L, Farokhzad OC, Langer R, Scott DW, von Andrian UH, Kishimoto TK.

Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E156-65. doi: 10.1073/pnas.1408686111. Epub 2014 Dec 29.

9.

Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.

Ilyinskii PO, Roy CJ, O'Neil CP, Browning EA, Pittet LA, Altreuter DH, Alexis F, Tonti E, Shi J, Basto PA, Iannacone M, Radovic-Moreno AF, Langer RS, Farokhzad OC, von Andrian UH, Johnston LP, Kishimoto TK.

Vaccine. 2014 May 19;32(24):2882-95. doi: 10.1016/j.vaccine.2014.02.027. Epub 2014 Mar 1.

10.

Generation of a universal CD4 memory T cell recall peptide effective in humans, mice and non-human primates.

Fraser CC, Altreuter DH, Ilyinskii P, Pittet L, LaMothe RA, Keegan M, Johnston L, Kishimoto TK.

Vaccine. 2014 May 19;32(24):2896-903. doi: 10.1016/j.vaccine.2014.02.024. Epub 2014 Feb 26.

11.

The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers.

Harrill AH, Roach J, Fier I, Eaddy JS, Kurtz CL, Antoine DJ, Spencer DM, Kishimoto TK, Pisetsky DS, Park BK, Watkins PB.

Clin Pharmacol Ther. 2012 Aug;92(2):214-20. doi: 10.1038/clpt.2012.40. Epub 2012 Jun 27.

12.

M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis.

Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, Duffner J, Zhao G, Smith S, Galcheva-Gargova Z, Karlgren J, Dussault N, Kwan RY, Moy E, Barnes M, Long A, Honan C, Qi YW, Shriver Z, Ganguly T, Schultes B, Venkataraman G, Kishimoto TK.

PLoS One. 2011;6(6):e21106. doi: 10.1371/journal.pone.0021106. Epub 2011 Jun 16.

13.

Bioactivity screening of partially desulfated low-molecular-weight heparins: a structure/activity relationship study.

Roy S, Lai H, Zouaoui R, Duffner J, Zhou H, P Jayaraman L, Zhao G, Ganguly T, Kishimoto TK, Venkataraman G.

Glycobiology. 2011 Sep;21(9):1194-205. doi: 10.1093/glycob/cwr053. Epub 2011 Apr 22.

PMID:
21515908
14.

Non-invasive detection of a small number of bioluminescent cancer cells in vivo.

Kim JB, Urban K, Cochran E, Lee S, Ang A, Rice B, Bata A, Campbell K, Coffee R, Gorodinsky A, Lu Z, Zhou H, Kishimoto TK, Lassota P.

PLoS One. 2010 Feb 23;5(2):e9364. doi: 10.1371/journal.pone.0009364.

15.

M118--a rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes.

Kishimoto TK, Qi YW, Long A, Capila I, Sasisekharan R, Guerrero L, Fier I, Roach J, Venkataraman G.

Thromb Haemost. 2009 Nov;102(5):900-6. doi: 10.1160/TH09-02-0105.

PMID:
19888526
16.

Outbreak of adverse reactions associated with contaminated heparin.

Blossom DB, Kallen AJ, Patel PR, Elward A, Robinson L, Gao G, Langer R, Perkins KM, Jaeger JL, Kurkjian KM, Jones M, Schillie SF, Shehab N, Ketterer D, Venkataraman G, Kishimoto TK, Shriver Z, McMahon AW, Austen KF, Kozlowski S, Srinivasan A, Turabelidze G, Gould CV, Arduino MJ, Sasisekharan R.

N Engl J Med. 2008 Dec 18;359(25):2674-84. doi: 10.1056/NEJMoa0806450. Epub 2008 Dec 3. Erratum in: N Engl J Med. 2010 Mar 18;362(11):1056.

17.

Contaminated heparin associated with adverse clinical events and activation of the contact system.

Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J, Sasisekharan R.

N Engl J Med. 2008 Jun 5;358(23):2457-67. doi: 10.1056/NEJMoa0803200. Epub 2008 Apr 23. Erratum in: N Engl J Med. 2010 Mar 18;362(11):1056.

18.

Small molecule LFA-1 antagonists compete with an anti-LFA-1 monoclonal antibody for binding to the CD11a I domain: development of a flow-cytometry-based receptor occupancy assay.

Woska JR Jr, Last-Barney K, Rothlein R, Kroe RR, Reilly PL, Jeanfavre DD, Mainolfi EA, Kelly TA, Caviness GO, Fogal SE, Panzenbeck MJ, Kishimoto TK, Giblin PA.

J Immunol Methods. 2003 Jun 1;277(1-2):101-15.

PMID:
12799043
19.

Decreased expression of IL-2 in central and effector CD4 memory cells during progression to AIDS in rhesus macaques.

Koopman G, Niphuis H, Newman W, Kishimoto TK, Maino VC, Heeney JL.

AIDS. 2001 Dec 7;15(18):2359-69.

PMID:
11740186
20.

A small-molecule antagonist of LFA-1 blocks a conformational change important for LFA-1 function.

Woska JR Jr, Shih D, Taqueti VR, Hogg N, Kelly TA, Kishimoto TK.

J Leukoc Biol. 2001 Aug;70(2):329-34.

PMID:
11493627
21.

The cytoplasmic domain of L-selectin participates in regulating L-selectin endoproteolysis.

Matala E, Alexander SR, Kishimoto TK, Walcheck B.

J Immunol. 2001 Aug 1;167(3):1617-23.

22.

ADAM17 but not ADAM10 mediates tumor necrosis factor-alpha and L-selectin shedding from leukocyte membranes.

Condon TP, Flournoy S, Sawyer GJ, Baker BF, Kishimoto TK, Bennett CF.

Antisense Nucleic Acid Drug Dev. 2001 Apr;11(2):107-16.

PMID:
11334139
23.

Antibody to intercellular adhesion molecule 1 (CD54) decreases survival and not lung injury in baboons with sepsis.

Welty-Wolf KE, Carraway MS, Huang YC, Simonson SG, Kantrow SP, Kishimoto TK, Piantadosi CA.

Am J Respir Crit Care Med. 2001 Mar;163(3 Pt 1):665-73.

PMID:
11254521
24.
25.

Dynamic expression of L-selectin in cell-to-cell interactions between neutrophils and endothelial cells in vitro.

Liu Q, Kishimoto TK, Mainolfi E, Deleon RP, Myers C, Moretz RC.

Exp Cell Res. 1998 Aug 25;243(1):87-93.

PMID:
9716452
26.

Identification of N-terminal residues on P-selectin glycoprotein ligand-1 required for binding to P-selectin.

Liu W, Ramachandran V, Kang J, Kishimoto TK, Cummings RD, McEver RP.

J Biol Chem. 1998 Mar 20;273(12):7078-87.

27.

Calmodulin regulates L-selectin adhesion molecule expression and function through a protease-dependent mechanism.

Kahn J, Walcheck B, Migaki GI, Jutila MA, Kishimoto TK.

Cell. 1998 Mar 20;92(6):809-18.

28.

Antibody to E- and L-selectin does not prevent lung injury or mortality in septic baboons.

Carraway MS, Welty-Wolf KE, Kantrow SP, Huang YC, Simonson SG, Que LG, Kishimoto TK, Piantadosi CA.

Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):938-49.

PMID:
9517615
30.

Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease.

Haught WH, Mansour M, Rothlein R, Kishimoto TK, Mainolfi EA, Hendricks JB, Hendricks C, Mehta JL.

Am Heart J. 1996 Jul;132(1 Pt 1):1-8.

PMID:
8701848
31.

Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors.

Arribas J, Coodly L, Vollmer P, Kishimoto TK, Rose-John S, Massagué J.

J Biol Chem. 1996 May 10;271(19):11376-82.

32.

Neutrophil rolling altered by inhibition of L-selectin shedding in vitro.

Walcheck B, Kahn J, Fisher JM, Wang BB, Fisk RS, Payan DG, Feehan C, Betageri R, Darlak K, Spatola AF, Kishimoto TK.

Nature. 1996 Apr 25;380(6576):720-3.

PMID:
8614468
33.
35.

Signaling functions of L-selectin. Enhancement of tyrosine phosphorylation and activation of MAP kinase.

Waddell TK, Fialkow L, Chan CK, Kishimoto TK, Downey GP.

J Biol Chem. 1995 Jun 23;270(25):15403-11.

36.

Regulation of L-selectin expression by membrane proximal proteolysis.

Kishimoto TK, Kahn J, Migaki G, Mainolfi E, Shirley F, Ingraham R, Rothlein R.

Agents Actions Suppl. 1995;47:121-34.

PMID:
7540352
37.

Potentiation of the oxidative burst of human neutrophils. A signaling role for L-selectin.

Waddell TK, Fialkow L, Chan CK, Kishimoto TK, Downey GP.

J Biol Chem. 1994 Jul 15;269(28):18485-91.

38.

Changes in subcellular localization and surface expression of L-selectin, alkaline phosphatase, and Mac-1 in human neutrophils during stimulation with inflammatory mediators.

Borregaard N, Kjeldsen L, Sengeløv H, Diamond MS, Springer TA, Anderson HC, Kishimoto TK, Bainton DF.

J Leukoc Biol. 1994 Jul;56(1):80-7.

PMID:
7517990
39.

In vivo and in vitro functional examination of a conserved epitope of L- and E-selectin crucial for leukocyte-endothelial cell interactions.

Bargatze RF, Kurk S, Watts G, Kishimoto TK, Speer CA, Jutila MA.

J Immunol. 1994 Jun 15;152(12):5814-25.

PMID:
7515914
40.
41.

Cross-linking of ICAM-1 induces co-signaling of an oxidative burst from mononuclear leukocytes.

Rothlein R, Kishimoto TK, Mainolfi E.

J Immunol. 1994 Mar 1;152(5):2488-95.

PMID:
7510744
42.

Integrins, ICAMs, and selectins: role and regulation of adhesion molecules in neutrophil recruitment to inflammatory sites.

Kishimoto TK, Rothlein R.

Adv Pharmacol. 1994;25:117-69. Review. No abstract available.

PMID:
7515640
43.

E-selectin supports neutrophil rolling in vitro under conditions of flow.

Abbassi O, Kishimoto TK, McIntire LV, Anderson DC, Smith CW.

J Clin Invest. 1993 Dec;92(6):2719-30.

44.

Treatment of inflammation with anti-ICAM-1.

Rothlein R, Mainolfi EA, Kishimoto TK.

Res Immunol. 1993 Nov-Dec;144(9):735-9; discussion 754-62. Review. No abstract available.

PMID:
7909166
45.

Monoclonal antibody to L-selectin attenuates neutrophil accumulation and protects ischemic reperfused cat myocardium.

Ma XL, Weyrich AS, Lefer DJ, Buerke M, Albertine KH, Kishimoto TK, Lefer AM.

Circulation. 1993 Aug;88(2):649-58.

PMID:
7687936
46.

Neutrophil adhesion to endothelial cells.

Abbassi O, Kishimoto TK, McIntire LV, Smith CW.

Blood Cells. 1993;19(2):245-59; discussion 259-60.

PMID:
7508770
47.

Elevated levels of circulating adhesion molecules in IDDM patients and in subjects at risk for IDDM.

Lampeter ER, Kishimoto TK, Rothlein R, Mainolfi EA, Bertrams J, Kolb H, Martin S.

Diabetes. 1992 Dec;41(12):1668-71.

PMID:
1280239
48.

Expression and regulation of L-selectin on eosinophils from human adults and neonates.

Smith JB, Kunjummen RD, Kishimoto TK, Anderson DC.

Pediatr Res. 1992 Oct;32(4):465-71.

PMID:
1279509
49.

Characterization of the bovine peripheral lymph node homing receptor: a lectin cell adhesion molecule (LECAM).

Walcheck B, White M, Kurk S, Kishimoto TK, Jutila MA.

Eur J Immunol. 1992 Feb;22(2):469-76.

PMID:
1371468
50.

The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1.

Berg EL, Yoshino T, Rott LS, Robinson MK, Warnock RA, Kishimoto TK, Picker LJ, Butcher EC.

J Exp Med. 1991 Dec 1;174(6):1461-6.

Supplemental Content

Loading ...
Support Center